Some discrepancies exist between outcomes indicated in trial registration and later publications

September 01, 2009

Comparison of the primary outcomes of registered clinical trials with their subsequent publication appears to show some discrepancies, according to a study in the September 2 issue of JAMA.

In 2005, the International Committee of Medical Journal Editors (ICMJE) adopted a policy requiring researchers to deposit information about randomized controlled trials into a clinical trials registry before study participants enrolled as a precondition for publication of the study's findings in member journals. "One of the main objectives of trial registration is to help achieve transparency in results and make information about the existence and design of clinical trials publicly available," the authors provide as background information. "This policy should permit knowledge sharing about the key elements of clinical trials and help decrease the risk of selective reporting of outcomes that was previously identified in published results of RCTs [randomized controlled trials]."

Sylvain Mathieu, M.D., of Hopital Bichat-Claude Bernard, Paris and colleagues conducted a search of the MEDLINE via PubMed to identify randomized controlled trials in three areas: cardiology, rheumatology, and gastroenterology, that were indexed in 2008 in the 10 general medical journals and specialty medical journals with the highest impact factors. The researchers sought to compare the primary outcomes specified in trial registries with those reported in the published articles and to determine whether outcome reporting bias favored significant primary outcomes. Of the 323 included articles, 114 (35.3 percent) were published in general medical journals and 209 (64.7 percent) in specialty journals.

"A total of 147 trials (45.5 percent) were adequately registered (i.e., registered before the end of the trial, with the primary outcome clearly specified)," the authors write. "Trial registration was lacking for 89 published reports (27.6 percent), 45 trials (13.9 percent) were registered after the completion of the study, 39 (12.1 percent) were registered with no or an unclear description of the primary outcome, and 3 (0.9 percent) were registered after the completion of the study and had an unclear description of the primary outcome." The authors note that the proportion of registered trials was greater for the general medical journals than the specialty publications. "Among articles with trials adequately registered, 31 percent (46 of 147) showed some evidence of discrepancies between the outcomes registered and the outcomes published." Of those 46 articles, the authors report "19 of 23 (82.6 percent) had a discrepancy that favored statistically significant results (i.e., a new, statistically significant primary outcome was introduced in the published article or a nonsignificant primary outcome was omitted or not defined as the primary outcome in the published article)."

"Trial registration provides a good opportunity for editors, peer-reviewers, and policy makers to identify outcome reporting bias, and other deviations from the planned study to prevent such distortions from reaching publication," the authors write.

"In conclusion, although trial registration is now the rule, careful implementation of trial registration, with full involvement of authors, editors, and reviewers is necessary to ensure publication of quality, unbiased results."
-end-
(JAMA. 2009;302[9]:977-984. Available pre-embargo to the media at www.jamamedia.org.)

Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

The JAMA Network Journals

Related Clinical Trials Articles from Brightsurf:

Nearly 1 in 5 cancer patients less likely to enroll in clinical trials during pandemic
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic.

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.

Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.

Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.

Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.

Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.

Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.

When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.

New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.

Read More: Clinical Trials News and Clinical Trials Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.